AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage

Results to be presented at the 38th European Cystic Fibrosis Conference. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 8, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of […]

AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

First cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 3, 2014 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was […]

AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, May 19 2015 Link here. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015. Corporate Update • […]

AmpliPhi Biosciences Announces M. Scott Salka as New CEO

Link here. Biotechnology entrepreneur brings extensive business development and fundraising expertise to leading bacteriophage-based antibacterials company. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, April 30, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Scott Salka has been appointed […]

AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY — March 31, 2015. Link here. Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, March 31, 2015 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP […]

FierceBiotech – Intrexon partner AmpliPhi raises $13M for antibiotic R&D

March 11, 2015 | By Damian Garde – Link here. AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections. The Richmond, VA, biotech is issuing nearly 79 million shares at $0.165 apiece to a group of investors including partner Intrexon ($XON), […]

AmpliPhi BioSciences Corporation Announces $13 Million Financing

March 10, 2015 05:07 PM Eastern Daylight Time. Link here. RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY–(BUSINESS WIRE)–AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, […]

AmpliPhi Provides Shareholder Update

Bacteriophage-based Antibacterial Therapies to Treat Drug Resistant Infections Advancing towards Human Clinical Studies 2015 Uplisting to Major Exchange Expected Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, January 05, 2015 – Link here. AmpliPhi BioSciences Corporation (OTCQB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, provided an update to […]

AmpliPhi Announces Appointment of New Board Member

RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 Link here. AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election […]

AmpliPhi Announces Appointment of New Board Member – Wendy Johnson

Link here. RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 –AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election to […]